Retatrutide
About 25% weight loss in a final-stage trial. Not approved as of fall 2026.
Grade A: Strong human proof
Big trials in people, and it worked.
The grade is for the use people talk about, not for every use. Filed under: Fat loss (GLP-1 family).
How it works
Hits three hormone targets: GLP-1, GIP and glucagon.
How it was given in studies
Injection under the skin, in the trials. It is not approved.
This is what the studies did. It is not a how-to. Source: Final-stage trial. NEJM, 2026; Mid-stage trial. NEJM, 2023.
What studies saw
In a final-stage trial of 2,339 adults over 80 weeks, weight fell about 25% at the highest amount, against 4% on placebo. Knee pain and sleep apnea also improved.
The trade-off
Stomach and gut side effects were the most common. Not approved, so anything sold now is unverified.
When it showed up, in studies
About 25% of body weight over 80 weeks in a final-stage trial.
Sources
Put this grade on your site
Copy the line below. The badge links back to this page, so readers can check the sources. It grades the compound in studies. It does not rate any product or seller.
<a href="https://www.workedinrats.com/compounds/retatrutide"><img src="https://www.workedinrats.com/badge/retatrutide.svg" alt="Retatrutide: grade A, strong human proof. Worked in Rats" width="300" height="72"></a>
Keep going
We show what studies found. We never tell you what to take. Doses vary by study. Check the sources and talk to a doctor.